The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma

K. Parameswaran, L. Hong, A. Fanat, R. Watson, G. Obminski, D. P. Snider, P. M. O'Byrne (Hamilton, Canada)

Source: Annual Congress 2003 - State of the art in assessing airway inflammation
Session: State of the art in assessing airway inflammation
Session type: Poster Discussion
Number: 2658
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Parameswaran, L. Hong, A. Fanat, R. Watson, G. Obminski, D. P. Snider, P. M. O'Byrne (Hamilton, Canada). The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma. Eur Respir J 2003; 22: Suppl. 45, 2658

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

The Cys-LT1 receptor antagonist, pranlukast, attenuates allergen-induced increase in airway eosinophils and bone marrow derived eosinophil/basophil progenitors in subjects with atopic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 349s
Year: 2003

Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
Source: Eur Respir J 2013; 41: 46-52
Year: 2013



The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects
Source: Eur Respir J 2007; 30: Suppl. 51, 490s
Year: 2007

A leukotriene antagonist, montelukast, reduces in vitro LTD4 increases in peripheral blood eosinophil progenitor colonies in atopic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 531s
Year: 2001

The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma
Source: Eur Respir J 2002; 20: 1080-1087
Year: 2002



The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine
Source: Annual Congress 2007 - New drugs for asthma
Year: 2007


The development of an airway hyperresponsiveness (AHR) depends on mast cells following sensitization without adjuvant
Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis
Year: 2006


The inflammation and the airway hyperresponsiveness in allergic asthma is inhibited by IL-10 dependent mechanism
Source: Annual Congress 2007 - Mouse models of allergic airway inflammation
Year: 2007


Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice
Source: Annual Congress 2008 - Novel mechanisms in the pathogenesis of pulmonary inflammation
Year: 2008

IPL576,092 reduces allergen-induced late asthmatic responses, sputum eosinophilia and airway hyperresponsiveness in mild asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 104s
Year: 2003

Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Inhalation of mannitol, used as a model for exercise-induced bronchoconstriction (EIB), causes release of leukotrienes and a mast cell marker in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 102s
Year: 2001

Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010

Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma
Source: Eur Respir J 2002; 19: 997-1002
Year: 2002



Relationship between allergen-induced increase of AHR to bradykinin, expression of the proliferation marker Ki-67 and eosinophils in bronchial mucosa of atopic asthmatics
Source: Annual Congress 2003 - Modulation of bronchial hyperreactivity and immune response in the airways
Year: 2003